U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523763) titled 'Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer' on April 06.
Brief Summary: Patients with clinical stage II-III dMMR/MSI colorectal adenocarcinoma will be treated with low-dose immunotherapy: nivolumab 100 mg or pembrolizumab 100 mg. The duration of treatment is 6 months.
Study Start Date: March 22, 2024
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer (MSI-H)
Colorectal Cancer (CRC)
Intervention:
DRUG: Nivolumab or pembrolizumab
Nivolumab 100 mg infusion OR Pembrolizumab 100 mg infusion
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Blokhin's Russian Cancer Research Cente...